

PRESS RELEASE

Hansa Biopharma to host conference call to provide Year-End report for 2021 and Business Update

Lund, Sweden January 20, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its Year-End report 2021 at 8:00 CET on February 3, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the Year-End results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Presentations" and will also be made available online after the call. [Link to presentation](#)

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 850 55 83 51

United Kingdom: +44 333 300 92 60

United States: +1 646 722 49 56

The webcast will be available on <https://streams.eventcdn.net/hansa/year-end-report/>

Updated Calendar and Events 2022

Feb 3, 2022	Year-End report for Jan - Dec 2021
Mar 10, 2022	Erik Penser Bolagsdag, Stockholm
Mar 10, 2022	Redeye Investor Forum, Gothenburg
Mar 15, 2022	Carnegie Healthcare Seminar 2022, Stockholm
Mar 31, 2022	Redeye Investor Forum, Malmö
April 7, 2022	Annual Report 2021
April 21, 2022	Interim Report for January-March 2022
April 21, 2022	Kempen Life Sciences Conference 2022, Amsterdam
April 27, 2022	Redeye Orphan Drugs 2022, Stockholm
May, 2022	RBC Global Healthcare Conference 2022, New York City
June 16, 2022	Annual General Meeting 2022
July 21, 2022	Half year 2022 report
Oct 20, 2022	Interim Report for January-September 2022

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.

For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

Katja Margell, *Head of Corporate Communications*

M: +46 (0) 768-198 326

E: katja.margell@hansabiopharma.com